ASCO Daily News: Dr. Cora Sternberg article about prostate cancer
Is There Sufficient Evidence to Intensify Systemic Therapy in Patients With Prostate Cancer Who Have M1 by PSMA-PET but Negative Conventional Imaging?
Key Points:
Prostate-specific membrane antigen PET
scans (PSMA-PET) are more sensitive than conventional imaging (CI);
however, the clinical trial data that established the standard of care
for patients with metastatic hormone-sensitive prostate cancer used CI
as the arbiter of decision-making.
Integrating PSMA-PET
into everyday clinical practice without prospective evidence derived
from clinical trials poses significant challenges to physicians as well
as potential quality-of-life effects to their patients.
These challenges will only be surmounted at the completion of new and
ongoing clinical trials in which PSMA-PET replaces currently accepted CI
endpoints.
Full Article may be accessed at the following URL:
